Drug Trial Radar · NCT06385678
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
47
Actual
Start
Jul 5, 2024
Primary completion
Dec 2025
Study completion Aug 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation.
Conditions
- Advanced KRAS G12D Mutant Solid Tumors
Interventions
HRS-4642Drug
administrated per dose level in which the patients are assigned
AdebrelimabDrug
administrated per dose level in which the patients are assigned
SHR-9839Drug
administrated per dose level in which the patients are assigned
Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for InjectionDrug
administered as prescribed by the investigator.
Cetuximab Solution for InfusionDrug
administrated per dose level in which the patients are assigned
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase IB: Safety endpoints: adverse events (AEs).Time frame: 24 months
- Phase IB: Maximum tolerated dose (MTD)Time frame: From Day 1 to Day 21
- Phase IB:Recommended phase 2 dose (RP2D)Time frame: 24 months
- Phase II: Overall response rate (ORR).Time frame: 24 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.